Steglatro

Discussion in 'Merck' started by anonymous, Aug 19, 2018 at 4:07 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Why was Steglatro not mentioned on earnings call for Merck? The drug is doing unbelievable
     

  2. anonymous

    anonymous Guest

    Steglatro is perhaps the worse launch in the history of Merck considering it competes in the greatest growth category of drugs in diabetes. Terrible launch
     
  3. anonymous

    anonymous Guest

    Could not agree more although the latest numbers are showing a substantial improvement in Steglatro.
     
  4. anonymous

    anonymous Guest

    Cannot believe my increase with Steglatro. Simply amazing
     
  5. anonymous

    anonymous Guest

    My latest numbers showed nRXs surpassed Invokana.
     
  6. anonymous

    anonymous Guest

    it all started at the launch when the sales leader said “sales force will not take time to make pharmacy calls”
    And a major differential is the coupon offering....
    Now that was a very stupid move!
     
  7. anonymous

    anonymous Guest

    You're all a bunch of stupid robot fucks. Can't think past the end of your nose. Keep those verbatims going shits for brains.
     
  8. anonymous

    anonymous Guest

    How is Steglatro doing ?
     
  9. anonymous

    anonymous Guest

    FAILURE TO LAUNCH
     
  10. anonymous

    anonymous Guest

    My numbers are on par with Januvia
     
  11. anonymous

    anonymous Guest

    What do you mean on par with Januvia
     
  12. anonymous

    anonymous Guest

    What does that mean. My numbers are on par with Januvia
     
  13. anonymous

    anonymous Guest

    Steglatro again was not mentioned on earnings call. What is going on with this drug?
     
  14. anonymous

    anonymous Guest

    Primary Care is dead to this company, thus Stegnotro does not get air time
     
  15. anonymous

    anonymous Guest

    When you launch a new entry in March of this year into the biggest growth category in diabetes, the analysts want to know how you are performing. They do not care whether primary care has a position at Merck and Januvia was mentioned on the call so it does not make sense that Steglatro was not even mentioned.
     
  16. anonymous

    anonymous Guest

    Ummmm let’s see
    Chronic care, your days are numbered and this time if you do not see it, you deserve what happens to you.
     
  17. anonymous

    anonymous Guest

    You are correct the division will very soon be dissolved The trigger point occurs six months prior to patent expiration of diabetic products. So long and good bye!
     
  18. anonymous

    anonymous Guest

    Steglatro will be the key to diabetes future. And what a future that will be
     
  19. anonymous

    anonymous Guest

    Steglatro has been out almost a year. Certainly out of launch mode. What is the market share within the SGLT2 class and how much money is it generating?
     
  20. decade501

    decade501 New Member

    Joined:
    Nov 18, 2018
    Messages:
    11
    Likes Received:
    0
    How’s being a cc rep? Got an offer last week and idk what to do